On February 12, 2022, Shanghai Yizhong Pharmaceutical Co.Ltd(688091) and Qingdao Baheal Medical Inc(301015) signed a cooperation agreement in Qingdao. The two sides will cooperate on the commercialization of Shanghai Yizhong Pharmaceutical Co.Ltd(688091) ‘s tumor innovative drug “paclitaxel polymer micelles for injection” (hereinafter referred to as “paclitaxel micelles”) Zisheng, so as to jointly promote the accessibility of domestic tumor innovative drugs and benefit many tumor patients in China.
In the field of domestic innovative drugs in full bloom, the commercialization environment is changing rapidly. Cooperation with professional third-party commercialization platforms to achieve win-win has become the mainstream choice of innovative pharmaceutical enterprises. At the signing ceremony, Zhou Jinsong, chairman of Shanghai Yizhong Pharmaceutical Co.Ltd(688091) , said: ” Shanghai Yizhong Pharmaceutical Co.Ltd(688091) is committed to developing a new generation of innovative drugs to provide patients with safe, effective and affordable high-quality drugs to meet the urgent treatment needs. Paclitaxel micelles are our first listed products. In the stage of commercialization, we hope to cooperate with Qingdao Baheal Medical Inc(301015) Such a professional third-party commercial platform cooperates to jointly promote innovative drug products to enter the market and benefit more cancer patients. “
As a professional health brand commercialization platform, Qingdao Baheal Medical Inc(301015) based on the three core competencies of “brand operation with category insight, customer management of full data platform and mechanism to support long-term operation”, by providing professional brand commercialization escort services for innovative drug enterprises, it can enable innovative new drug products to quickly enter the application scenario and break the dilemma of commercialization of innovative drugs after listing. At present Qingdao Baheal Medical Inc(301015) not only forms a rich brand matrix in OTC, great health, Otx and other prescription drugs, but also undertakes high-quality products such as Xeloda and trokai, which operate Roche pharmaceutical, and betanli, a patented drug of anstelai.
Fu Gang, chairman of Qingdao Baheal Medical Inc(301015) , said: ” Qingdao Baheal Medical Inc(301015) As a third-party commercial platform with brand operation as the core, it has strict selection standards. The first is to eliminate pseudo innovation and select products that can really optimize clinical application scenarios. The second is to evaluate the technical barriers of products based on professional evaluation ability to avoid falling into the dilemma of low-level repetition. The third is to do a good job in factor allocation with ecological coordination and select products that can truly complement and cooperate with Baiyang resources for commercial operation. “
“Paclitaxel micelle Zisheng is the third generation of paclitaxel, which has significant curative effect and good safety. Its distribution in tumor tissue is much higher than that in blood. It is a revolutionary product. Qingdao Baheal Medical Inc(301015) it will make factor configuration according to the characteristics of its life cycle, formulate reasonable commercial solutions and help the product release value.” Fu Gang further said.
The cooperation between Shanghai Yizhong Pharmaceutical Co.Ltd(688091) and Qingdao Baheal Medical Inc(301015) will integrate the strong R & D strength and excellent commercialization ability of innovative drugs. The strong cooperation between the two sides is expected to bring new cooperation examples to the commercialization of innovative drugs.
